| pubmed-article:8847043 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8847043 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8847043 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8847043 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:8847043 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:8847043 | lifeskim:mentions | umls-concept:C0443146 | lld:lifeskim |
| pubmed-article:8847043 | lifeskim:mentions | umls-concept:C0332120 | lld:lifeskim |
| pubmed-article:8847043 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:8847043 | pubmed:dateCreated | 1996-10-24 | lld:pubmed |
| pubmed-article:8847043 | pubmed:abstractText | We performed a prospective nonrandomized clinical trial to demonstrate that Interferon (IFN) treatment of individuals with chronic hepatitis C virus (HCV) positive hepatitis (CH-C) and serologic and/or histologic evidence of autoimmune dysregulation is feasible and whether the benefits of successfully treating CH-C are outweighed by the risk of exacerbating Autoimmune Chronic Active Hepatitis (ACAH). | lld:pubmed |
| pubmed-article:8847043 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8847043 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847043 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8847043 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847043 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847043 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847043 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847043 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8847043 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8847043 | pubmed:issn | 0172-6390 | lld:pubmed |
| pubmed-article:8847043 | pubmed:author | pubmed-author:Van ThielD... | lld:pubmed |
| pubmed-article:8847043 | pubmed:author | pubmed-author:MolloyP JPJ | lld:pubmed |
| pubmed-article:8847043 | pubmed:author | pubmed-author:ZuhdiNN | lld:pubmed |
| pubmed-article:8847043 | pubmed:author | pubmed-author:FriedlanderLL | lld:pubmed |
| pubmed-article:8847043 | pubmed:author | pubmed-author:FagiuoliSS | lld:pubmed |
| pubmed-article:8847043 | pubmed:author | pubmed-author:CaraceniPP | lld:pubmed |
| pubmed-article:8847043 | pubmed:author | pubmed-author:WrightH IHI | lld:pubmed |
| pubmed-article:8847043 | pubmed:author | pubmed-author:KaniaR JRJ | lld:pubmed |
| pubmed-article:8847043 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8847043 | pubmed:volume | 42 | lld:pubmed |
| pubmed-article:8847043 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8847043 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8847043 | pubmed:pagination | 900-6 | lld:pubmed |
| pubmed-article:8847043 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:meshHeading | pubmed-meshheading:8847043-... | lld:pubmed |
| pubmed-article:8847043 | pubmed:articleTitle | Interferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation. | lld:pubmed |
| pubmed-article:8847043 | pubmed:affiliation | Oklahoma Transplant Institute, Baptist Medical Center of Oklahoma, Oklahoma City, USA. | lld:pubmed |
| pubmed-article:8847043 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8847043 | pubmed:publicationType | Clinical Trial | lld:pubmed |
